和铂医药（苏州）有限公司

和铂医药是一家全球运营的创新型生物医药公司，致力于为全球患者提供聚焦于肿瘤免疫与免疫性疾病领域 的创新药物。
我们基于医学和病患需求，利用全球专利的两个全人源抗体转基因小鼠平台（Harbour Mice^®）研发针对肿瘤和免疫性疾病的突破性创新疗法，包括全人源抗体药物（H2L2）以及基于重链抗体（HCAb）的双靶点抗体（HBICE^TM）。我们通过自主创新及多元化 的外部研发合作与项目引进，专注于创新药物产品管线的研发和建设。
目前和铂医药在中国、美国、荷兰等多地开展全球化运营。我们还将核心科技平台授权给全球范围内的其他制药公司和学术机构。

Harbour BioMed is a Global Biotherapeutics Company primarily focused on inventing, developing, manufacturing and commercializing novel therapeutics for the treatment of serious medical conditions in oncology, and immunology. HBM has labs and business operations in Cambridge in the US, Rotterdam in Netherlands and Shanghai and Suzhou, China. We aim to help people with complex and debilitating conditions by identifying unmet medical and patient needs and driving strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. Our approach is shaped by our experienced team’s capability in delivering highly specialized treatments and forging close relationships with physicians and patients to understand the NextGen treatments that will provide hope to patients and their families around the world.